Gene Therapy For Inherited Genetic Disorders Market Forecast Reveals Where Future Industry Value Will Be Created
Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.
Gene Therapy For Inherited Genetic Disorders Market Size Forecast: How Large Could The Market Become By 2030?
The market for gene therapy targeting inherited genetic disorders has experienced swift expansion over recent years. Projected to rise from $4.05 billion in 2025 to $4.84 billion in 2026, this represents a compound annual growth rate (CAGR) of 19.3%. Historically, this growth was driven by factors such as the restricted access to sophisticated gene therapy methods, dependence on traditional approaches for treating genetic conditions, a growing incidence of inherited genetic diseases, foundational clinical investigations involving viral vectors, and heightened awareness surrounding the management of rare diseases.
The gene therapy market for inherited genetic disorders is projected to experience significant expansion in the coming years, reaching a value of $9.69 billion by 2030, with a compound annual growth rate (CAGR) of 19.0%. This forecasted growth is driven by advancements in novel viral vectors and gene editing tools, the broadening scope of RNA-based treatments, increased use of ex vivo stem cell therapies, heightened investment in customized gene therapies, and enhanced capabilities in hospitals and specialty clinics for administering these therapies. Key trends shaping the forecast period include the proliferation of viral vector-based approaches for rare genetic conditions, greater adoption of ex vivo gene therapy techniques, rising utilization of RNA-focused therapeutics, a growing emphasis on addressing neurological and ophthalmic disorders, and the integration of personalized medicine into gene therapy strategies.
Download A Free Sample Report For Comprehensive Market Insights:
Gene Therapy For Inherited Genetic Disorders Market Expansion Drivers: What Is Shaping Future Growth?
The growing demand for tailored medical approaches is anticipated to accelerate the expansion of the gene therapy market focused on inherited genetic disorders. Personalized medicine involves adapting treatments to a patient’s genetic profile and individual characteristics in order to deliver optimized care. This trend is gaining momentum due to progress in genetic technologies, which have made it simpler and more cost-effective to customize therapies according to a person’s unique genetic composition. Such customization boosts gene therapy by aligning treatments with each patient’s distinct genetic blueprint, enabling precise gene targeting and delivery while improving efficacy and minimizing adverse effects. For example, in February 2024, the Personalized Medicine Coalition—a nonprofit organization based in the United States—reported that the U.S. Food and Drug Administration (FDA) approved 16 new personalized therapies for rare disease patients in 2023, compared with 6 in 2022. Among these newly approved personalized treatments for 2023 were seven cancer drugs and three medications targeting other conditions. Consequently, the rising demand for personalized medicine is fueling growth in the gene therapy market for inherited genetic disorders.
Gene Therapy For Inherited Genetic Disorders Market Segments: Where Are The Largest Growth Opportunities?
The gene therapy for inherited genetic disorders market covered in this report is segmented –
1) By Type: Viral Vector-Based Therapies, Gene Editing Techniques, Ribonucleic Acid-Based Therapies, Ex Vivo Gene Therapy
2) By Application: Inherited Metabolic Disorders, Neurological Disorders, Cardiovascular Disorders, Musculoskeletal Disorders, Ophthalmic Disorders
3) By End-User: Hospitals, Specialty Clinics, Research Institutes, Other End-Users
Subsegments:
1) By Viral Vector-Based Therapies: Adenovirus Vectors, Adeno-Associated Virus (AAV) Vectors, Lentivirus Vectors
2) By Gene Editing Techniques: Zinc Finger Nucleases (ZFNs), Transcription Activator-Like Effector Nucleases (TALENs), Meganucleases
3) By Ribonucleic Acid-Based Therapies: Small Interfering Ribonucleic Acid, Antisense Oligonucleotides (ASOs), Messenger Ribonucleic Acid (mRNA) Therapies
4) By Ex Vivo Gene Therapy: Hematopoietic Stem Cell Gene Therapy, Mesenchymal Stem Cell Gene Therapy, Induced Pluripotent Stem Cell (iPSC) Therapy
Gene Therapy For Inherited Genetic Disorders Market Strategic Trends: What Is Defining The Next Phase Of Growth?
Key players in the gene therapy market for inherited genetic disorders are concentrating on developing advanced treatments, particularly ex-vivo CRISPR/Cas9-based gene-edited cell therapies, to address the growing need for one-time, potentially curative options that minimize reliance on lifelong blood transfusions, frequent hospital stays, and expensive chronic care for inherited blood and metabolic conditions. In this approach, a patient’s hematopoietic stem cells are collected and precisely modified using CRISPR/Cas9 technology to correct disease-causing genes or enhance regulatory elements that boost protective fetal hemoglobin; these edited cells are then reinfused, allowing them to engraft and deliver sustained therapeutic outcomes. A notable example occurred in December 2023 when Vertex Pharmaceuticals, a U.S.-based biopharmaceutical firm, secured approval from the U.S. Food and Drug Administration (FDA) and launched CASGEVY (exagamglogene autotemcel), a CRISPR/Cas9-based ex-vivo gene-edited cell therapy designed for sickle cell disease, an inherited genetic disorder. This therapy is derived from the patient’s own hematopoietic stem cells, which undergo gene editing to elevate fetal hemoglobin levels; its composition features autologous stem cells modified with CRISPR/Cas9, and its mechanism works by generating durable fetal hemoglobin concentrations that inhibit red blood cell sickling. Distinct characteristics include ex-vivo precise genome editing via CRISPR/Cas9 and a single administration that offers lasting effects; CASGEVY’s primary use is for severe sickle cell disease and similar indications under regulatory review, while clinical trials have demonstrated significant reductions in vaso-occlusive crises and transfusion needs compared to conventional treatments.
Gene Therapy For Inherited Genetic Disorders Market Major Participants And Competitive Dynamics
Major companies operating in the gene therapy for inherited genetic disorders market are Sanofi S.A., Novartis AG, Astellas Pharma Inc., Vertex Pharmaceuticals Incorporated, Genentech, Biomarin Pharmaceutical Inc, Sarepta Therapeutics Inc., Krystal Biotech Inc., Rocket Pharmaceuticals Inc., Sangamo Therapeutics Inc., REGENXBIO Inc., Passage Bio Inc., Voyager Therapeutics Inc., Generation Bio Co., Avrobio Inc, Editas Medicine Inc., MeiraGTx Holdings Plc, uniQure N.V., Intellia Therapeutics Inc., Bluebird Bio Inc, 4D Molecular Therapeutics Inc., CRISPR Therapeutics AG
Access The Complete Gene Therapy For Inherited Genetic Disorders Market Report:
Gene Therapy For Inherited Genetic Disorders Market Geographic Landscape: Which Region Dominates Industry Growth?
North America was the largest region in the gene therapy for inherited genetic disorders market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gene therapy for inherited genetic disorders market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
